NCT04806464View on ClinicalTrials.gov

Clinical Study of VG161 in Subjects with Advanced Primary Liver Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

March 16, 2021

Primary Completion Date

March 21, 2022

Study Completion Date

December 31, 2024

Conditions
Primary Liver Cancer
Interventions
DRUG

Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))

Intratumoral injection only. The dosing date can be the Day 1 only or Days 1 through 5.

Trial Locations (1)

Unknown

RECRUITING

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

CNBG-Virogin Biotech (Shanghai) Ltd.

INDUSTRY